Search - tctmd.com

Displaying 181 - 200 of 367

Sort: Relevancy | Date

Presentation TCT 2017

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Presenter: Christopher B. Granger, Horst Sievert, Renu Virmani

October 30, 2017

Presentation TCT 2017

Case #6: LAA Closure - Device Embolization (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, Krzysztof Bartus

October 30, 2017

Presentation TCT 2017

LAA Closure III: Postprocedure and Beyond

Presenter: Russell A. Brandwein

October 30, 2017

Presentation TCT 2017

LAA Closure II: From Consultation to Procedure

Presenter: Russell A. Brandwein, Jessica Forman

October 30, 2017

Presentation TCT 2017

LAA Closure I: From Referral to Consultation

Presenter: Russell A. Brandwein, Lindsay Thomas

October 30, 2017

Presentation TCT 2017

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Presenter: David Hildick-Smith, Lars Sondergaard, Robert A. Byrne

October 29, 2017

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lariat

Presenter: Krzysztof Bartus, Randall J. Lee

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Presenter: Krzysztof Bartus, Yat-Yin Lam

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Presenter: Krzysztof Bartus, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Presenter: Krzysztof Bartus, Eustaquio Maria Onorato

November 01, 2016

Advertisement

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Case #6: LAA Closure - Device Embolization (With Discussion)

LAA Closure III: Postprocedure and Beyond

LAA Closure II: From Consultation to Procedure

LAA Closure I: From Referral to Consultation

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Special Tips and Tricks for LAA Closure Using the Lariat

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content